Publications by authors named "Martin Cranage"

Claim this Profile
I
Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?
Alberto Beretta, Martin Cranage, Donato Zipeto

Front Immunol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine.
Neil Berry, Maria Manoussaka, Claire Ham, Deborah Ferguson, Hannah Tudor, Martin P Cranage

PLoS Pathog· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissues.
Deborah Ferguson, Giada Mattiuzzo, Claire Ham, Richard Stebbings, Bo Li, Martin P Cranage

PLoS One· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDS.
Mark Page, Ruby Quartey-Papafio, Mark Robinson, Mark Hassall, Martin Cranage

PLoS One· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on "Influence of HLA-C expression level on HIV control".
Elisa Lo Monaco, Elisa Tremante, Priscilla Biswas, Martin P Cranage, Donato Zipeto

Science· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conditionally-live attenuated SIV upregulates global T effector memory cell frequency under replication permissive conditions.
Maria S Manoussaka, Neil Berry, Deborah Ferguson, Richard Stebbings, Mark Robinson, Martin P Cranage

Retrovirology· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally.
David J Lewis, Carol A Fraser, Abdel N Mahmoud, Rebecca C Wiggins, Maria Woodrow, Martin P Cranage

PLoS One· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection, quantification, and characterisation of HIV/SIV.
Neil Berry, Carolina Herrera, Martin Cranage

Methods Mol Biol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.
Martin P Cranage, Carol A Fraser, Alethea Cope, Paul F McKay, Michael S Seaman

Vaccine· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of mucosal immunity to HIV-1.
Vicky Jespers, Ali M Harandi, Jorma Hinkula, Donata Medaglini, Roger Le Grand, Martin Cranage

Expert Rev Vaccines· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses.
Rhonda M Curran, Louise Donnelly, Ryan J Morrow, Carol Fraser, Gavin Andrews, Martin Cranage

Vaccine· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reverse transcriptase inhibitors as potential colorectal microbicides.
Carolina Herrera, Martin Cranage, Ian McGowan, Peter Anton, Robin J Shattock

Antimicrob Agents Chemother· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modern mucosal vaccines, adjuvants and microbicides.
Martin P Cranage, Maria Manoussaka

Expert Rev Anti Infect Ther· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carriers for the delivery of a vaccine against respiratory syncytial virus.
Martin Cranage, Geraldine Taylor

Expert Opin Biol Ther· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macaques infected long-term with attenuated simian immunodeficiency virus (SIVmac) remain resistant to wild-type challenge, despite declining cytotoxic T lymphocyte responses to an immunodominant epitope.
Sally A Sharpe, Alethea Cope, Stuart Dowall, Neil Berry, Claire Ham, Martin Cranage

J Gen Virol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An assessment of different DNA delivery systems for protection against respiratory syncytial virus infection in the murine model: gene-gun delivery induces IgG in the lung.
Julia A Tree, Gary Bembridge, Sam Hou, Geraldine Taylor, Elizabeth Fashola-Stone, Martin P Cranage

Vaccine· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
Sally Sharpe, Tomás Hanke, Anne Tinsley-Bown, Mike Dennis, Stuart Dowall, Martin Cranage

Virology· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infection of macaques with simian immunodeficiency virus induces a species-specific antibody response to major histocompatibility complex class I and class II molecules.
Natasha Polyanskaya, Sally A Sharpe, Nicola Cook, Sharon Leech, Martin P Cranage

J Gen Virol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the efficacy of early versus late viral proteins in vaccination against SIV.
Koert J Stittelaar, Rob A Gruters, Martin Schutten, Carel A van Baalen, Geert van Amerongen, Martin Cranage

Vaccine· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication.
Bo Peng, Rebecca Voltan, Lulu Lim, Yvette Edghill-Smith, Sanjay Phogat, Martin Cranage

J Virol· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses.
Sally Sharpe, Anthony Fooks, John Lee, Kevin Hayes, Christopher Clegg, Martin Cranage

Virology· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity.
Sally Sharpe, Natasha Polyanskaya, Mike Dennis, Gerd Sutter, Tomáš Hanke, Martin Cranage

J Gen Virol· September 2001

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
Christine B Bruce, Alan Akrigg, Sally A Sharpe, Tomáš Hanke, Gavin W G Wilkinson, Martin P Cranage

J Gen Virol· October 1999

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis